{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:07:19Z","timestamp":1772168839353,"version":"3.50.1"},"update-to":[{"DOI":"10.12688\/f1000research.144903.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000}},{"DOI":"10.12688\/f1000research.144903.2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000}}],"reference-count":118,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns3:p>Group A Streptococcus (GAS) is a widely distributed bacterium that is Gram-positive and serves as the primary cause of acute rheumatic fever (ARF) episodes. Rheumatic heart disease (RHD) is a sequela resulting from repeated ARF attacks which are also caused by repeated GAS infections. ARF\/RHD morbidity and mortality rates are incredibly high in low- and middle-income countries. This is closely related to poor levels of sanitation which causes the enhanced incidence of GAS infections. Management of carditis in RHD cases is quite challenging, particularly in developing countries, considering that medical treatment is only palliative, while definitive treatment often requires more invasive procedures with high costs. Preventive action through vaccination against GAS infection is one of the most effective steps as a solution in reducing RHD morbidity and mortality due to curative treatments are expensive. Various developments of M-protein-based GAS vaccines have been carried out over the last few decades and have recently begun to enter the clinical stage. Nevertheless, this vaccination generates cross-reactive antibodies that might trigger ARF assaults as a result of the resemblance between the M-protein structure and proteins found in many human tissues. Consequently, the development of a vaccine utilizing L-Rhamnose derived from the poly-rhamnose backbone of Group A Carbohydrate (GAC) commenced. The L-Rhamnose-based vaccine was chosen due to the absence of the Rhamnose biosynthesis pathway in mammalian cells including humans thus this molecule is not found in any body tissue. Recent pre-clinical studies reveal that L-Rhamnose-based vaccines provide a protective effect by increasing IgG antibody titers without causing cross-reactive antibodies in test animal tissue. These findings demonstrate that the L-Rhamnose-based vaccine possesses strong immunogenicity, which effectively protects against GAS infection while maintaining a significantly higher degree of safety.<\/ns3:p>","DOI":"10.12688\/f1000research.144903.3","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T11:30:07Z","timestamp":1738236607000},"page":"132","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Unveiling the Group A Streptococcus Vaccine-Based L-Rhamnose from Backbone of Group A Carbohydrate: Current Insight Against Acute Rheumatic Fever to Reduce the Global Burden of Rheumatic Heart Disease"],"prefix":"10.12688","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8280-3324","authenticated-orcid":false,"given":"Ade Meidian","family":"Ambari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5320-358X","authenticated-orcid":false,"given":"Faqrizal Ria","family":"Qhabibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dwita Rian","family":"Desandri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bambang","family":"Dwiputra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pirel Aulia","family":"Baravia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indira Kalyana","family":"Makes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basuni","family":"Radi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41541-023-00730-x","article-title":"Update on the development of Group A Streptococcus vaccines.","volume":"8","author":"S Ajay Castro","year":"2023 Sep 14","journal-title":"NPJ Vaccines."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"h3443","DOI":"10.1136\/bmj.h3443","article-title":"Acute rheumatic fever.","volume":"351","author":"R Webb","year":"2015 Jul 14","journal-title":"BMJ."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"30-35","DOI":"10.1136\/heartasia-2015-010709","article-title":"Evaluation of the American Heart Association 2015 revised Jones criteria versus existing guidelines.","volume":"8","author":"D Kumar","year":"2016 Feb 29","journal-title":"Heart Asia."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"503-507","DOI":"10.1016\/j.autrev.2014.01.036","article-title":"Diagnostic criteria of acute rheumatic fever.","volume":"13","author":"R Burke","year":"2014 Apr","journal-title":"Autoimmun. Rev."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11936-017-0513-y","article-title":"Group A Streptococcus, Acute Rheumatic Fever and Rheumatic Heart Disease: Epidemiology and Clinical Considerations.","volume":"19","author":"L Z\u00fchlke","year":"2017 Feb 11","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1806-1818","DOI":"10.1161\/CIR.0000000000000205","article-title":"Revision of the Jones Criteria for the Diagnosis of Acute Rheumatic Fever in the Era of Doppler Echocardiography.","volume":"131","author":"M Gewitz","year":"2015 May 19","journal-title":"Circulation."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"408-416","DOI":"10.1097\/BOR.0b013e32835461d3","article-title":"Streptococcus and rheumatic fever.","volume":"24","author":"M Cunningham","year":"2012 Jul","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"314-329","DOI":"10.3109\/08830185.2014.917411","article-title":"Rheumatic fever, autoimmunity, and molecular mimicry: The streptococcal connection.","volume":"33","author":"M Cunningham","year":"2014 Jul 4","journal-title":"Int. Rev. Immunol."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"171-177","DOI":"10.1038\/nrcardio.2012.197","article-title":"Revisiting the pathogenesis of rheumatic fever and carditis.","volume":"10","author":"R Tandon","year":"2013 Mar 15","journal-title":"Nat. Rev. Cardiol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1397-1416","DOI":"10.1016\/j.jacc.2018.06.063","article-title":"Rheumatic Heart Disease Worldwide: JACC Scientific Expert Panel.","volume":"72","author":"D Watkins","year":"2018 Sep 18","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3618-3620","DOI":"10.1128\/JCM.02129-15","article-title":"M-protein analysis of streptococcus pyogenes isolates associated with acute rheumatic fever in New Zealand.","volume":"53","author":"D Williamson","year":"2015 Nov","journal-title":"J. Clin. Microbiol."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.00115","article-title":"Angiotensin Converting Enzyme Inhibitors (ACEIs) Decrease the Progression of Cardiac Fibrosis in Rheumatic Heart Disease Through the Inhibition of IL-33\/sST2.","volume":"7","author":"A Ambari","year":"2020 Jul 28","journal-title":"Front. Cardiovasc. Med."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e1004266","DOI":"10.1371\/journal.ppat.1004266","article-title":"Host Responses to Group A Streptococcus: Cell Death and Inflammation.","volume":"10","author":"J Tsatsaronis","year":"2014 Aug 28","journal-title":"PLoS Pathog."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11886-019-1099-7","article-title":"Rheumatic Mitral Valve Stenosis: Diagnosis and Treatment Options.","volume":"21","author":"N Wunderlich","year":"2019 Mar 28","journal-title":"Curr. Cardiol. Rep."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"49-58","DOI":"10.1038\/nrcardio.2012.157","article-title":"Screening for rheumatic heart disease: Current approaches and controversies.","volume":"10","author":"K Roberts","year":"2013 Jan 13","journal-title":"Nat. Rev. Cardiol."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"102740","DOI":"10.1016\/j.autrev.2020.102740","article-title":"Rheumatic heart disease: A review of the current status of global research activity.","volume":"20","author":"L Dooley","year":"2021 Feb","journal-title":"Autoimmun. Rev."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11886-016-0773-2","article-title":"Rheumatic Heart Disease in the Twenty-First Century.","volume":"18","author":"B Woldu","year":"2016 Oct 27","journal-title":"Curr. Cardiol. Rep."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"162-168","DOI":"10.1097\/HCO.0000000000000269","article-title":"Update on rheumatic heart disease.","volume":"31","author":"B Yanagawa","year":"2016 Mar","journal-title":"Curr. Opin. Cardiol."},{"key":"ref19","first-page":"203-210","article-title":"A Study on Rheumatic Fever.","volume":"5","author":"R Ali","year":"2018","journal-title":"Int. J. Res. Anal. Rev."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s11886-012-0343-1","article-title":"Echocardiographic screening for subclinical rheumatic heart disease remains a research tool pending studies of impact on prognosis.","volume":"15","author":"L Z\u00fchlke","year":"2013 Mar 22","journal-title":"Curr. Cardiol. Rep."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"81-94","DOI":"10.1016\/j.jacc.2022.09.050","article-title":"Rheumatic Heart Disease.","volume":"81","author":"S Dougherty","year":"2023 Jan","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"806-816","DOI":"10.1161\/CIRCULATIONAHA.117.032561","article-title":"Pregnancy outcomes in women with rheumatic mitral valve disease: Results from the registry of pregnancy and cardiac disease.","volume":"137","author":"I Van Hagen","year":"2018 Feb 20","journal-title":"Circulation."},{"key":"ref23","first-page":"70-75","article-title":"Streptococcal pharyngitis, rheumatic fever and rheumatic heart disease: Eight-year prospective surveillance in Rupnagar district of Punjab, India.","volume":"27","author":"R Kumar","year":"2014","journal-title":"Natl. Med. J. India."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1070-1073","DOI":"10.1093\/eurheartj\/ehu507","article-title":"The stark reality of rheumatic heart disease.","volume":"36","author":"J Carapetis","year":"2015 May 2","journal-title":"Eur. Heart J."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"69-87","DOI":"10.1007\/978-1-4471-6672-6_5","author":"T Yingchoncharoen","year":"2015","journal-title":"An Atlas of Mitral Valve Imaging."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11936-015-0390-1","article-title":"Assessment of Mitral Valve Disease: A Review of Imaging Modalities.","volume":"17","author":"S Motiwala","year":"2015 Jul 19","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"500-507","DOI":"10.1136\/heartjnl-2015-308091","article-title":"Update on percutaneous mitral commissurotomy.","volume":"102","author":"M Nunes","year":"2016 Apr 1","journal-title":"Heart."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"195-206","DOI":"10.1016\/B978-0-323-63982-8.00010-6","author":"S Ali","year":"2021","journal-title":"Acute Rheumatic Fever and Rheumatic Heart Disease."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13643-021-01748-9","article-title":"Preventive interventions to reduce the burden of rheumatic heart disease in populations at risk: a systematic review protocol.","volume":"10","author":"P Shimanda","year":"2021 Dec 8","journal-title":"Syst. Rev."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1-4","DOI":"10.1007\/s40256-013-0005-8","article-title":"A vaccine against streptococcus pyogenes: The potential to prevent rheumatic fever and rheumatic heart disease.","volume":"13","author":"L Guilherme","year":"2013 Feb","journal-title":"Am. J. Cardiovasc. Drugs."},{"key":"ref31","first-page":"1-27","article-title":"Group A Streptococcal Diseases and Their Global Burden.","author":"A Ralph","year":"2012"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"685-694","DOI":"10.1016\/S1473-3099(05)70267-X","article-title":"The global burden of group A streptococcal diseases.","volume":"5","author":"J Carapetis","year":"2005 Nov","journal-title":"Lancet Infect. Dis."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"rsos.201991","DOI":"10.1098\/rsos.201991","article-title":"A brief review on Group A Streptococcus pathogenesis and vaccine development.","volume":"8","author":"S Castro","year":"2021 Mar 10","journal-title":"R. Soc. Open Sci."},{"key":"ref34","article-title":"Global disease burden of group A Streptococcus.","author":"A Sanyahumbi","year":"2016"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1017\/S0950268818002285","article-title":"The fall and rise of Group A Streptococcus diseases.","volume":"147","author":"T Barnett","year":"2019 Aug 15","journal-title":"Epidemiol. Infect."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"492-501","DOI":"10.1161\/CIRCULATIONAHA.113.001477","article-title":"Acute Rheumatic Fever and Rheumatic Heart Disease.","volume":"128","author":"J Lawrence","year":"2013 Jul 30","journal-title":"Circulation."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.gheart.2013.08.008","article-title":"Estimates of the global burden of rheumatic heart disease.","volume":"8","author":"L Z\u00fchlke","year":"2013 Sep 1","journal-title":"Glob. Heart."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2982-3021","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study.","volume":"76","author":"G Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1789-1858","DOI":"10.1016\/S0140-6736(19)31047-5","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017.","volume":"392","author":"S James","year":"2018 Nov","journal-title":"Lancet."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1736-1788","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the Global Burden of Disease Study 2017.","volume":"392","author":"G Roth","year":"2018 Nov","journal-title":"Lancet."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"16-22","DOI":"10.1016\/j.acvd.2014.07.053","article-title":"Prevalence of rheumatic heart disease in young adults from New Caledonia.","volume":"108","author":"P Ledos","year":"2015 Jan","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"3127-3132","DOI":"10.1161\/CIRCULATIONAHA.112.092312","article-title":"Echocardiography screening for rheumatic heart disease in ugandan schoolchildren.","volume":"125","author":"A Beaton","year":"2012 Jun 26","journal-title":"Circulation."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"375-383","DOI":"10.1016\/j.ijcard.2015.06.145","article-title":"Incidence, prevalence and outcome of rheumatic heart disease in South Africa: A systematic review of contemporary studies.","volume":"199","author":"L Z\u00fchlke","year":"2015 Nov","journal-title":"Int. J. Cardiol."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"147-156","DOI":"10.2174\/1573403X11309020007","article-title":"Heart Failure in South America.","volume":"9","author":"A Bocchi","year":"2013 May 1","journal-title":"Curr. Cardiol. Rev."},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.17334\/jps.57302","article-title":"Acute Rheumatic Fever In Egyptian Children: A 30-Year Experience in a Tertiary Hospital.","volume":"6","author":"D Elamrousy","year":"2014 Jul 6","journal-title":"J. Pediatr. Sci."},{"key":"ref46","first-page":"555-558","article-title":"Acute Rheumatic Fever and Rheumatic Heart Disease Among Children \u2014 American Samoa, 2011\u20132012.","volume":"64","author":"A Beaudoin","year":"2015","journal-title":"MMWR Morb. Mortal Wkly Rep."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"719-727","DOI":"10.1093\/eurheartj\/ehp530","article-title":"Incidence and characteristics of newly diagnosed rheumatic heart disease in Urban African adults: Insights from the Heart of Soweto Study.","volume":"31","author":"K Sliwa","year":"2010 Mar 2","journal-title":"Eur. Heart J."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"264-301","DOI":"10.1128\/CMR.00101-13","article-title":"Disease manifestations and pathogenic mechanisms of group A Streptococcus.","volume":"27","author":"M Walker","year":"2014 Apr","journal-title":"Clin. Microbiol. Rev."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1279-1282","DOI":"10.1093\/cid\/cis847","article-title":"Clinical practice guideline for the diagnosis and management of group a streptococcal pharyngitis: 2012 update by the infectious diseases society of America.","volume":"55","author":"S Shulman","year":"2012 Nov 15","journal-title":"Clin. Infect. Dis."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"201-204","DOI":"10.1093\/cid\/ciz1000","article-title":"Streptococcus pyogenes pbp2x mutation confers reduced susceptibility to \u03b2-lactam antibiotics.","volume":"71","author":"K Vannice","year":"2020 Jun 24","journal-title":"Clin. Infect. Dis."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"983-992","DOI":"10.1093\/cid\/ciab597","article-title":"Health-Economic Value of Vaccination Against Group A Streptococcus in the United States.","volume":"74","author":"K Andrejko","year":"2022 Mar 23","journal-title":"Clin. Infect. Dis."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"10-19","DOI":"10.1038\/nm.4465","article-title":"The role of vaccines in preventing bacterial antimicrobial resistance.","volume":"24","author":"K Jansen","year":"2018 Jan 1","journal-title":"Nat. Med."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"6968-6978","DOI":"10.1016\/j.vaccine.2018.10.001","article-title":"An economic case for a vaccine to prevent group A streptococcus skin infections.","volume":"36","author":"J Cannon","year":"2018 Nov","journal-title":"Vaccine."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"877-883","DOI":"10.1093\/cid\/ciy1143","article-title":"The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics.","volume":"69","author":"J Vekemans","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"207-242","DOI":"10.1007\/82_2012_284","article-title":"Group A Streptococcal Vaccine Candidates: Potential for the Development of a Human Vaccine.","volume":"368","author":"A Henningham","year":"2012 Dec 19","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41541-023-00639-5","article-title":"Progress towards a glycoconjugate vaccine against Group A Streptococcus.","volume":"8","author":"K Burns","year":"2023 Mar","journal-title":"NPJ Vaccines."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1035-1043","DOI":"10.1038\/s41588-019-0417-8","article-title":"Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics.","volume":"51","author":"M Davies","year":"2019 Jun 27","journal-title":"Nat. Genet."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"336-346","DOI":"10.1021\/pr3005265","article-title":"Identification of potential universal vaccine candidates against group a streptococcus by using high throughput in silico and proteomics approach.","volume":"12","author":"A Sharma","year":"2013 Jan 4","journal-title":"J. Proteome Res."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1459-1470","DOI":"10.1586\/14760584.2015.1081817","article-title":"Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.","volume":"14","author":"M Good","year":"2015 Nov 2","journal-title":"Expert Rev. Vaccines."},{"key":"ref60","doi-asserted-by":"crossref","first-page":"19-26","DOI":"10.1016\/j.vaccine.2016.11.065","article-title":"Structure-based design of broadly protective group a streptococcal M protein-based vaccines.","volume":"35","author":"J Dale","year":"2017 Jan","journal-title":"Vaccine."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"E222-E229","DOI":"10.1111\/1469-0691.12134","article-title":"Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study.","volume":"19","author":"D Mcmillan","year":"2013 May","journal-title":"Clin. Microbiol. Infect."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"282-298","DOI":"10.1111\/mmi.13556","article-title":"The Group A Streptococcus serotype M2 pilus plays a role in host cell adhesion and immune evasion.","volume":"103","author":"J Tsai","year":"2017 Jan 14","journal-title":"Mol. Microbiol."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"176-183","DOI":"10.4103\/ijmm.IJMM_17_16","article-title":"Molecular Biology of Group A Streptococcus and its Implications in Vaccine Strategies.","volume":"35","author":"N Brahmadathan","year":"2017 Apr","journal-title":"Indian J. Med. Microbiol."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1138-1149","DOI":"10.4049\/jimmunol.2100286","article-title":"Design of Broadly Cross-Reactive M Protein\u2013Based Group A Streptococcal Vaccines.","volume":"207","author":"M Aranha","year":"2021 Aug 15","journal-title":"J. Immunol."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"e1009248","DOI":"10.1371\/journal.ppat.1009248","article-title":"Nonimmune antibody interactions of group a streptococcus M and M-like proteins.","volume":"17","author":"J Mills","year":"2021 Feb 25","journal-title":"PLoS Pathog."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"16155","DOI":"10.1038\/nmicrobiol.2016.155","article-title":"Conserved patterns hidden within group A Streptococcus M protein hypervariability recognize human C4b-binding protein.","volume":"1","author":"C Buffalo","year":"2016 Sep 5","journal-title":"Nat. Microbiol."},{"key":"ref67","article-title":"Vaccine-induced th1-type response protects against invasive group a Streptococcus infection in the absence of opsonizing antibodies.","volume":"11","author":"T Rivera-Hernandez","year":"2020 Apr 28","journal-title":"ASM Journals."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/vaccines8020210","article-title":"Opsonic activity of conservative versus variable regions of the group a streptococcus M protein.","volume":"8","author":"C Dai","year":"2020 May 7","journal-title":"Vaccines (Basel)."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3390\/vaccines11091510","article-title":"Streptococcus pyogenes: Pathogenesis and the Current Status of Vaccines.","volume":"11","author":"J Wang","year":"2023 Sep 21","journal-title":"Vaccines (Basel)."},{"key":"ref70","doi-asserted-by":"publisher","first-page":"47-59","DOI":"10.1016\/B978-0-323-85831-1.00004-8","article-title":"Rheumatic fever: From pathogenesis to vaccine perspectives. Translational Autoimmunity.","volume":"6","author":"L Guilherme","year":"2023","journal-title":"Advances in Autoimmune Rheumatic Diseases."},{"key":"ref71","article-title":"Current Approaches to Vaccine Development of Streptococcus pyogenes Introduction and Historical Perspective.","author":"N Harbison-Price","year":"2022"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1384-1392","DOI":"10.1016\/j.vaccine.2019.12.005","article-title":"Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study.","volume":"38","author":"E Pastural","year":"2020 Feb","journal-title":"Vaccine."},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1773-1779","DOI":"10.1016\/j.vaccine.2021.01.075","article-title":"Cross-reactive immunogenicity of group A streptococcal vaccines designed using a recurrent neural network to identify conserved M protein linear epitopes.","volume":"39","author":"J Spencer","year":"2021 Mar","journal-title":"Vaccine."},{"key":"ref74","doi-asserted-by":"publisher","first-page":"15084","DOI":"10.1038\/nrdp.2015.84","article-title":"Acute rheumatic fever and rheumatic heart disease.","volume":"2","author":"J Carapetis","year":"2016 Jan 14","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref75","doi-asserted-by":"publisher","first-page":"19-30","DOI":"10.1016\/B978-0-323-63982-8.00002-7","article-title":"Pathogenesis of Acute Rheumatic Fever.","author":"L Guilherme","year":"2021","journal-title":"Acute Rheumatic Fever and Rheumatic Heart Disease."},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.GPP3-0045-2018","article-title":"Molecular Mimicry, Autoimmunity, and Infection: The Cross-Reactive Antigens of Group A Streptococci and their Sequelae.","volume":"7","author":"M Cunningham","year":"2019 Jul 19","journal-title":"Microbiol Spectr."},{"key":"ref77","doi-asserted-by":"publisher","first-page":"3826-3836","DOI":"10.1074\/jbc.RA119.011258","article-title":"Structure-based group A streptococcal vaccine design: Helical wheel homology predicts antibody cross-reactivity among streptococcal M protein-derived peptides.","volume":"295","author":"M Aranha","year":"2020 Mar","journal-title":"J. Biol. Chem."},{"key":"ref78","doi-asserted-by":"publisher","first-page":"431-447","DOI":"10.1038\/s41579-023-00865-7","article-title":"Pathogenesis, epidemiology and control of Group A Streptococcus infection.","volume":"21","author":"S Brouwer","year":"2023 Jul 9","journal-title":"Nat. Rev. Microbiol."},{"key":"ref79","doi-asserted-by":"publisher","first-page":"19441-19457","DOI":"10.1074\/jbc.M117.815910","article-title":"The molecular mechanism of N-acetylglucosamine side-chain attachment to the Lancefield group A carbohydrate in Streptococcus pyogenes.","volume":"292","author":"J Rush","year":"2017 Nov","journal-title":"J. Biol. Chem."},{"key":"ref80","doi-asserted-by":"publisher","first-page":"87-100","DOI":"10.1097\/IM9.0000000000000044","article-title":"Site-Specific Conjugation of Cell Wall Polyrhamnose to Protein SpyAD Envisioning a Safe Universal Group A Streptococcal Vaccine.","volume":"3","author":"N Gao","year":"2021 Jun","journal-title":"Infect. Microbes Dis."},{"key":"ref81","doi-asserted-by":"publisher","first-page":"108279","DOI":"10.1016\/j.biotechadv.2023.108279","article-title":"Cell wall polysaccharides of streptococci: A genetic and structural perspective.","volume":"69","author":"Z Kampff","year":"2023 Dec","journal-title":"Biotechnol. Adv."},{"key":"ref82","doi-asserted-by":"publisher","first-page":"120736","DOI":"10.1016\/j.carbpol.2023.120736","article-title":"Elucidating the role of N-acetylglucosamine in Group A Carbohydrate for the development of an effective glycoconjugate vaccine against Group A Streptococcus.","volume":"311","author":"O Pitirollo","year":"2023 Jul","journal-title":"Carbohydr. Polym."},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02294-17","article-title":"Virulence role of the glcnac side chain of the lancefield cell wall carbohydrate antigen in non-m1-serotype group a streptococcus.","volume":"9","author":"A Henningham","year":"2018 Jan 30","journal-title":"mBio."},{"key":"ref84","doi-asserted-by":"publisher","first-page":"463-471","DOI":"10.1038\/s41589-019-0251-4","article-title":"Discovery of glycerol phosphate modification on streptococcal rhamnose polysaccharides.","volume":"15","author":"R Edgar","year":"2019 May 1","journal-title":"Nat. Chem. Biol."},{"key":"ref85","doi-asserted-by":"publisher","first-page":"178-212","DOI":"10.1021\/acsinfecdis.2c00559","article-title":"Development in the Concept of Bacterial Polysaccharide Repeating Unit-Based Antibacterial Conjugate Vaccines.","volume":"9","author":"R Rohokale","year":"2023 Feb 10","journal-title":"ACS Infect. Dis."},{"key":"ref86","doi-asserted-by":"publisher","first-page":"15237-15256","DOI":"10.1074\/jbc.RA119.009894","article-title":"Group A, B, C, and G Streptococcus Lancefield antigen biosynthesis is initiated by a conserved \u03b1-D-GlcNAc-\u03b2-1,4-L-rhamnosyltransferase.","volume":"294","author":"A Zorzoli","year":"2019 Oct","journal-title":"J. Biol. Chem."},{"key":"ref87","doi-asserted-by":"publisher","first-page":"464-479","DOI":"10.1093\/femsre\/fuw006","article-title":"Bacterial glycobiology: Rhamnose-containing cell wall polysaccharides in gram-positive bacteria.","volume":"40","author":"M Mistou","year":"2016 Jul","journal-title":"FEMS Microbiol. Rev."},{"key":"ref88","article-title":"Immunobiology of the Classical Lancefield Group A Streptococcal Carbohydrate Antigen.","volume":"89","author":"N Gao","year":"2021 Nov 16","journal-title":"Infect. Immun."},{"key":"ref89","article-title":"Structure and mechanism of biosynthesis of Streptococcus mutans cell wall polysaccharide.","author":"J Rush","year":"2024 May 9","journal-title":"bioRxiv."},{"key":"ref90","doi-asserted-by":"crossref","first-page":"1698-1703","DOI":"10.1073\/pnas.0711767105","article-title":"A direct link between carbohydrate utilization and virulence in the major human pathogen group A Streptococcus.","volume":"105","author":"S Shelburne","year":"2008 Feb 5","journal-title":"Proc. Natl. Acad. Sci."},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007348","article-title":"Streptococcal Lancefield polysaccharides are critical cell wall determinants for human Group IIA secreted phospholipase A2 to exert its bactericidal effects.","volume":"14","author":"V Hensbergen","year":"2018 Oct 15","journal-title":"PLoS Pathog."},{"key":"ref92","doi-asserted-by":"publisher","first-page":"729-740","DOI":"10.1016\/j.chom.2014.05.009","article-title":"The classical lancefield antigen of group A Streptococcus is a virulence determinant with implications for vaccine design.","volume":"15","author":"N Van Sorge","year":"2014 Jun","journal-title":"Cell Host Microbe."},{"key":"ref93","doi-asserted-by":"publisher","first-page":"129-135","DOI":"10.1086\/498618","article-title":"Group A Streptococcus (GAS) Carbohydrate as an Immunogen for Protection against GAS Infection.","volume":"193","author":"H Sabharwal","year":"2006 Jan","journal-title":"J. Infect. Dis."},{"key":"ref94","doi-asserted-by":"publisher","first-page":"281-290","DOI":"10.1021\/acsinfecdis.9b00347","article-title":"Group A Streptococcus Cell Wall Oligosaccharide-Streptococcal C5a Peptidase Conjugates as Effective Antibacterial Vaccines.","volume":"6","author":"S Wang","year":"2020 Feb 14","journal-title":"ACS Infect. Dis."},{"key":"ref95","doi-asserted-by":"publisher","first-page":"390-405","DOI":"10.1021\/acsinfecdis.0c00722","article-title":"Immunogenicity Assessment of Cell Wall Carbohydrates of Group A Streptococcus via Self-Adjuvanted Glyco-lipopeptides.","volume":"7","author":"F Khatun","year":"2021 Feb 12","journal-title":"ACS Infect. Dis."},{"key":"ref96","doi-asserted-by":"publisher","first-page":"104-114","DOI":"10.1016\/j.vaccine.2010.09.018","article-title":"Evaluation of a group a streptococcus synthetic oligosaccharide as vaccine candidate.","volume":"29","author":"A Kabanova","year":"2010 Dec","journal-title":"Vaccine."},{"key":"ref97","doi-asserted-by":"crossref","first-page":"38-48","DOI":"10.24170\/19-1-5362","article-title":"The pathophysiology of RHD and outstanding gaps.","volume":"19","author":"E Lumngwena","year":"2022","journal-title":"SA Heart."},{"key":"ref98","doi-asserted-by":"publisher","first-page":"101-123","DOI":"10.1016\/j.jtbi.2014.11.022","article-title":"Unresolved issues in theories of autoimmune disease using myocarditis as a framework.","volume":"375","author":"R Root-Bernstein","year":"2015 Jun","journal-title":"J. Theor. Biol."},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.2147\/VDT.S45037","article-title":"Challenges to developing effective streptococcal vaccines to prevent rheumatic fever and rheumatic heart disease.","volume":"39","author":"D Nitsche-Schmitz","year":"2014 May","journal-title":"Vaccine: Development and Therapy."},{"key":"ref100","doi-asserted-by":"publisher","first-page":"5803-5808","DOI":"10.1128\/IAI.68.10.5803-5808.2000","article-title":"T-Cell-Dependent Antibody Response to the Dominant Epitope of Streptococcal Polysaccharide, N-Acetyl-Glucosamine, Is Cross-Reactive with Cardiac Myosin.","volume":"68","author":"S Malkiel","year":"2000 Oct","journal-title":"Infect. Immun."},{"key":"ref101","doi-asserted-by":"publisher","first-page":"297-306","DOI":"10.1016\/S0002-9440(10)64373-8","article-title":"Induction of Myocarditis and Valvulitis in Lewis Rats by Different Epitopes of Cardiac Myosin and Its Implications in Rheumatic Carditis.","volume":"160","author":"J Galvin","year":"2002 Jan","journal-title":"Am. J. Pathol."},{"key":"ref102","doi-asserted-by":"publisher","first-page":"217-224","DOI":"10.1172\/JCI7132","article-title":"Cytotoxic mAb from rheumatic carditis recognizes heart valves and laminin.","volume":"106","author":"J Galvin","year":"2000 Jul 15","journal-title":"J. Clin. Invest."},{"key":"ref103","doi-asserted-by":"publisher","first-page":"345-385","DOI":"10.1146\/annurev-immunol-020711-075041","article-title":"Brain-reactive antibodies and disease.","volume":"31","author":"B Diamond","year":"2013 Mar 21","journal-title":"Annu. Rev. Immunol."},{"key":"ref113","doi-asserted-by":"publisher","first-page":"1661-1668","DOI":"10.4161\/hv.28350","article-title":"Polysaccharide-specific B cell responses to vaccination in humans.","volume":"10","author":"R Mitchell","year":"2014 Jun 4","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref114","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41541-021-00409-1","article-title":"Combined effects of glycan chain length and linkage type on the immunogenicity of glycoconjugate vaccines.","volume":"6","author":"C Anish","year":"2021 Dec 10","journal-title":"NPJ Vaccines."},{"key":"ref115","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3390\/pharmaceutics14081671","article-title":"Protein-Based Adjuvants for Vaccines as Immunomodulators of the Innate and Adaptive Immune Response: Current Knowledge, Challenges, and Future Opportunities.","volume":"14","author":"D D\u00edaz-Dinamarca","year":"2022 Aug 11","journal-title":"Pharmaceutics."},{"key":"ref116","doi-asserted-by":"publisher","first-page":"1814-1824","DOI":"10.1080\/21645515.2015.1043501","article-title":"Safety assessment of adjuvanted vaccines: Methodological considerations.","volume":"11","author":"F Da Silva","year":"2015 Jul 3","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref117","doi-asserted-by":"publisher","first-page":"454-475","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants.","volume":"20","author":"B Pulendran","year":"2021 Jun 6","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref118","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fcimb.2021.808005","article-title":"Immunobiology of Carbohydrates: Implications for Novel Vaccine and Adjuvant Design Against Infectious Diseases.","volume":"11","author":"G Stefanetti","year":"2022 Jan 18","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref104","doi-asserted-by":"publisher","first-page":"143-216","DOI":"10.1016\/S0065-2318(07)61004-X","article-title":"Deoxy Sugars: Occurrence and Synthesis.","volume":"61","author":"R Lederkremer","year":"2007","journal-title":"Adv. Carbohydr. Chem. Biochem."},{"key":"ref105","doi-asserted-by":"publisher","first-page":"946-962","DOI":"10.1111\/mmi.13169","article-title":"GacA is essential for Group A Streptococcus and defines a new class of monomeric dTDP-4-dehydrorhamnose reductases (RmlD).","volume":"98","author":"S Beek","year":"2015 Dec 1","journal-title":"Mol.Microbiol."},{"key":"ref106","doi-asserted-by":"publisher","first-page":"951-964","DOI":"10.1111\/mmi.14197","article-title":"Streptococcal dTDP-L-rhamnose biosynthesis enzymes: functional characterization and lead compound identification.","volume":"111","author":"S Beek","year":"2019 Apr 31","journal-title":"Mol. Microbiol."},{"key":"ref107","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.3390\/molecules27165315","article-title":"Rhamnose-Containing Compounds: Biosynthesis and Applications.","volume":"27","author":"S Li","year":"2022 Aug 20","journal-title":"Molecules."},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1128\/JB.00728-19","article-title":"Disruption of L-rhamnose biosynthesis results in severe growth defects in streptococcus mutans.","volume":"202","author":"A Bischer","year":"2020 Feb 25","journal-title":"J. Bacteriol."},{"key":"ref109","doi-asserted-by":"publisher","first-page":"103815","DOI":"10.1016\/j.bioorg.2020.103815","article-title":"Gold nanoparticles morphology does not affect the multivalent presentation and antibody recognition of Group A Streptococcus synthetic oligorhamnans.","volume":"99","author":"O Pitirollo","year":"2020 Jun","journal-title":"Bioorg. Chem."},{"key":"ref110","doi-asserted-by":"publisher","first-page":"53-64","DOI":"10.1007\/s10719-017-9798-z","article-title":"Investigating the candidacy of the serotype specific rhamnan polysaccharide based glycoconjugates to prevent disease caused by the dental pathogen Streptococcus mutans.","volume":"35","author":"F Michael","year":"2018 Feb 2","journal-title":"Glycoconj J."},{"key":"ref111","article-title":"Recombinant Group A Carbohydrate backbone embedded 1 into Outer Membrane 2 Vesicles is a potent vaccine candidate targeting Group A Streptococcus from 3 Streptococcus pyogenes and Streptococcus dysgalactiae subsp. equisimilis.","author":"S Castro","year":"2021 Nov 13","journal-title":"bioRxiv."},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00618-16","article-title":"Differing efficacies of lead group A streptococcal vaccine candidates and full-length M protein in cutaneous and invasive disease models.","volume":"7","author":"T Rivera-Hernandez","year":"2016 Jul 6","journal-title":"MBio."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/13-132\/v3\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/13-132\/v3\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/13-132\/v3\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T05:00:21Z","timestamp":1739509221000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/13-132\/v3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":118,"URL":"https:\/\/doi.org\/10.12688\/f1000research.144903.3","relation":{"has-version":[{"id-type":"doi","id":"10.12688\/f1000research.144903.2","asserted-by":"subject"},{"id-type":"doi","id":"10.12688\/f1000research.144903.1","asserted-by":"subject"}],"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.177425.r363559","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.177425.r363559","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.177425.r363558","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/13-132\/v3#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.173666.r335591, Arif Nur Muhammad Ansori, Universitas Airlangga, Surabaya, East Java, 29 Oct 2024, version 2, 1 approved, 1 approved with reservations","URL":"https:\/\/f1000research.com\/articles\/13-132\/v2#referee-response-335591","order":0,"name":"referee-response-335591","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.177425.r363559, Mark Kaddumukasa, Makerere University, Kampala, Central Region, 14 Feb 2025, version 3, indexed","URL":"https:\/\/f1000research.com\/articles\/13-132\/v3#referee-response-363559","order":1,"name":"referee-response-363559","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}